Login to Your Account

Amag eyes broader Feraheme bid

By Randy Osborne
Staff Writer

Tuesday, May 2, 2017

Amag Pharmaceuticals Inc. missed the consensus mark on first-quarter sales of Makena but nailed all the primary and secondary endpoints in the phase III trial testing the firm's approved Feraheme.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription